DataMeds buys cancer lab Helomics for $1.5M to enter oncology
What's the deal? DataMeds AIDealroom has a profile for this one. Try Dealroom →, formerly Wellgistics HealthDealroom has a profile for this one. Try Dealroom →, has acquired Helomics CorporationDealroom has a profile for this one. Try Dealroom → from Axe ComputeDealroom has a profile for this one. Try Dealroom → in a deal valued at about $1.5 million, closed on September 11, 2026. DataMeds paid with 636,328 common shares and a $1,363,672 convertible promissory note maturing in 2029, making the Pittsburgh oncology lab a wholly owned subsidiary.
What's changing hands? Helomics runs a CLIA/CAP-certified precision medicine oncology laboratory and a contract research organisation (CRO) central lab services business. DataMeds also gains $1.5 million in cash, with no third-party debt or significant unpaid payables.
What's the endgame? DataMeds, a Tampa-based health IT company, wants to extend beyond GLP-1 side-effect and Long COVID management into oncology. It plans to grow Helomics past tumour profiling and chemosensitivity testing into cancer screening, molecular profiling, and nutritional support for patients.
The company frames the move as a play for the $40 billion US cancer diagnostics and treatment market, with proceeds also funding its Health Lives Here campaign.
Why now? The deal marks a strategic reshuffle for both sides. Axe Compute — the former Predictive Oncology — sheds its remaining cancer testing operations to focus on scaling its neocloud AI infrastructure and GPU-as-a-service business, while keeping an equity stake in DataMeds.
The fine print: The convertible note carries 7% annual interest and an adjustable $1.00 per-share conversion price, subject to shareholder approval and anti-dilution protections. The seller agreed to a 12-month lock-up on the securities and a six-month voting commitment aligned with DataMeds' board recommendations.
What could go wrong? DataMeds enters oncology from a weak financial position. TipRanks'Dealroom has a profile for this one. Try Dealroom → AI analyst rates the stock underperform, citing sharp revenue contraction, extreme losses, negative equity, and sustained cash burn.
The signal: The transaction shows the widening split between AI infrastructure and healthcare services. As Axe Compute pivots to selling compute, its cancer lab lands with a buyer betting that oncology diagnostics — not GPUs — is where it can carve out value.
Read more: tipranks.com
Image credit: Generated with Gemini
